Salivary Defense Factors in Herpes Simplex Virus Infection
H. Välimaa1,2,*,
M. Waris3,
V. Hukkanen2,
M.F.J. Blankenvoorde4,5,
A.V. Nieuw Amerongen4, and
J. Tenovuo1
1 Department of Cariology, Institute of Dentistry,
2 Department of Virology,
3 Laboratory of Biophysics, Institute of Biomedicine, University of Turku, Turku, Finland;
4 Department of Oral Biochemistry, ACTA, Amsterdam, the Netherlands; and
5 currently at Aventis Pharma, Medical Department, Hoevelaken, the Netherlands;
View larger version (26K):
[in a new window]
|
Figure 1. Anti-HSV immunoglobulins in serum and saliva. Recurrent labial herpes (RLH). (a) Anti-HSV IgG levels in sera were significantly higher (p = 0.0005; Mann-Whitney U-test) in HSV-seropositive subjects with recurrent labial herpes than in asymptomatic seropositive subjects. (b) Anti-HSV IgA levels in saliva were low in all groups, whereas anti-HSV IgG levels were clearly detectable in both HSV-seropositive groups. There was a clear difference (p = 0.042; Mann-Whitney U-test) in the levels of salivary anti-HSV IgG between subjects with and those without recurrent labial herpes (endpoint titer ± SE).
|
|
View larger version (33K):
[in a new window]
|
Figure 2. Cell-protective and neutralization assays. Recurrent labial herpes (RLH). (a) There were no differences in the cell-protective activity of saliva between the groups. Saliva applied before infection reduced the number of plaque-forming units (PFU) detected in cell cultures by an average of 50 to 60%. The cultures were infected with 100 PFU, and the numbers of PFU detected in the cultures are illustrated. (b) Saliva of asymptomatic HSV-seropositive subjects neutralized HSV more efficiently than saliva of subjects with recurrences (p = 0.05; Mann-Whitney U-test). The percent of neutralization is illustrated.
|
|
Copyright © 2002 Institutional Access Guidelines
